During the past decade, Herlev Hospital, Onkologisk Afdeling R conducted 1 clinical trials. In the 10-year time frame, 1 clinical trials started and 0 clinical trials were completed, i.e. on average, 0% percent of trials that started reached the finish line to date. In the past 5 years, 0 clinical trials started and 0 clinical trials were completed. i.e. 0% of trials that started reached the finish line.

According to Clinical.Site data, the most researched conditions in "Herlev Hospital, Onkologisk Afdeling R" are "Renal Cell Cancer" (1 trials) and "Small Cell Lung Cancer" (1 trials). Many other conditions were trialed in "Herlev Hospital, Onkologisk Afdeling R" in a lesser frequency.

Most popular intervention types in "Herlev Hospital, Onkologisk Afdeling R" are "Drug" (2 trials). Other intervention types were less common.

The name of intervention was led by "Amrubicin" (1 trials), "Avelumab (MSB0010718C)" (1 trials), "Axitinib (AG-013736)" (1 trials), "Sunitinib" (1 trials) and "Topotecan" (1 trials). Other intervention names were less common.

The vast majority of trials in "Herlev Hospital, Onkologisk Afdeling R" are 2 trials for "All" genders.

Currently, there are NaN active trials in "Herlev Hospital, Onkologisk Afdeling R". undefined are not yet recruiting, undefined are recruiting, 1 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 1 completed trials in Herlev Hospital, Onkologisk Afdeling R, undefined suspended trials, and undefined terminated clinical trials to date.

Out of the total trials that were conducted in Herlev Hospital, Onkologisk Afdeling R, 0 "Phase 1" clinical trials were conducted, 0 "Phase 2" clinical trials and 2 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".